Skip to main content
Clinical Trials/NCT04434885
NCT04434885
Unknown
Not Applicable

Axial Involvement in Psoriatic Arthritis Cohort

Charite University, Berlin, Germany2 sites in 2 countries400 target enrollmentJuly 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psoriatic Arthritis
Sponsor
Charite University, Berlin, Germany
Enrollment
400
Locations
2
Primary Endpoint
The prevalence of axial involvement by local investigator
Last Updated
3 years ago

Overview

Brief Summary

This is a multinational multicenter cross-sectional study in patients with a definite diagnosis of PsA. The population of interest will consist of 400 adult patients diagnosed with PsA and fulfilling the classification criteria for PsA and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs). Participating rheumatologists are encouraged to include consecutive PsA patients not treated with biologic or a targeted synthetic disease-modifying antirheumatic drug because of their potential impact on active inflammatory changes in the axial skeleton, which will be the focus of the current study. Patients will be recruited prospectively in selected study centres and will undergo study-related examinations including imaging of the axial skeleton (X-rays and magnetic resonance imaging). Collected data will serve as a basis for the judgement on the presence or absence of axial involvement by the local investigator and, independently, by the central study committee.

Detailed Description

Background. Involvement of the axial skeleton (of sacroiliac joints and / or spine) is one of the frequent manifestations associated with psoriatic skin disease along with involvement of peripheral musculoskeletal structures (peripheral arthritis, enthesitis, dactylitis), which are usually referred to as psoriatic arthritis (PsA). Depending on the definition used, the prevalence of axial disease varies from 25% to 70% of patients with PsA. There is an urgent need for an evidence-based definition and a unified and widely accepted nomenclature for axial involvement in PsA that would allow defining a homogeneous subgroup of patients in the heterogeneous PsA population. Aim and study objectives. To develop a data-driven definition of axial involvement in PsA based on cross-sectional evaluation of patients with a diagnosis of PsA fulfilling the CASPAR criteria. The study objectives are: to determine the prevalence of axial involvement in a cohort of patients with PsA; to identify the frequency of imaging findings suggestive of inflammatory involvement of axial skeleton in PsA; to identify factors (clinical, lab, imaging) associated with the presence of axial involvement in PsA. Study design and study population. This is a multinational multicenter cross-sectional study in patients with a definite diagnosis of PsA. The population of interest will consist of 400 adult patients diagnosed with PsA and fulfilling the classification criteria for PsA and not receiving biological or targeted synthetic disease-modifying antirheumatic drugs (b or tsDMARDs). Participating rheumatologists are encouraged to include consecutive PsA patients not treated with biologic or a targeted synthetic disease-modifying antirheumatic drug because of their potential impact on active inflammatory changes in the axial skeleton, which will be the focus of the current study. Patients will be recruited prospectively in selected study centres and will undergo study-related examinations including imaging of the axial skeleton (X-rays and magnetic resonance imaging). Collected data will serve as a basis for the judgement on the presence or absence of axial involvement by the local investigator and, independently, by the central study committee. Analysis and study outcomes. The prevalence of axial involvement in a cohort of patients with PsA according to the local and central assessment will be calculated in PsA patients presenting with peripheral involvement (the primary analysis population) as well as in the entire group. The prevalence of axial involvement as assessed by the local investigator in PsA patients presenting with peripheral involvement will be the primary outcome of the study. The agreement between local and central judgements will be analyzed. A sub-analysis of a group presenting without peripheral involvement (i.e., pure axial disease) will be performed. The frequency of imaging findings (on MRI and X-rays) suggestive of inflammatory involvement of axial skeleton (sacroiliac joints and spine) in PsA according to the local and central assessment will be calculated. The agreement between local and central judgements will be analyzed. Parameters associated with the presence of axial involvement in PsA will be explored as well. The diagnostic / classification value of each parameter will be evaluated.

Registry
clinicaltrials.gov
Start Date
July 1, 2021
End Date
December 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Denis Poddubnyy

Professor of Rheumatology

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • Age \>=18 years.
  • Definite diagnosis of PsA.
  • Fulfilment of the CASPAR criteria for PsA.
  • Duration of PsA symptoms ≤10 years.
  • Written informed consent.

Exclusion Criteria

  • Unable or unwilling to give informed consent or to comply with the protocol.
  • Current or past treatment with biologic or a targeted synthetic disease-modifying antirheumatic drug (DMARDs).
  • Contraindications for MRI and/or plain X-ray examination of sacroiliac joints and spine.

Outcomes

Primary Outcomes

The prevalence of axial involvement by local investigator

Time Frame: Baseline

The frequency of axial involvement (global judgment) as assessed by the local investigator in PsA patients

Secondary Outcomes

  • The frequency of imaging findings suggestive of axial involvement(Baseline)
  • The frequency of axial involvement by the central committee(Baseline)

Study Sites (2)

Loading locations...

Similar Trials